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Dendritic cells (DCs) are the most potent antigen-presenting cells capable of priming 
naïve T-cells. Its C-type lectin receptor, DC-SIGN, regulates a wide range of immune 
functions. Along with its role in HIV-1 pathogenesis through complement opsonization 
of the virus, DC-SIGN has recently emerged as an adaptor for complement protein C1q 
on the surface of immature DCs via a trimeric complex involving gC1qR, a receptor 
for the globular domain of C1q. Here, we have examined the nature of interaction 
between C1q and DC-SIGN in terms of domain localization, and implications of C1q–
DC-SIGN-gC1qR complex formation on HIV-1 transmission. We first expressed and 
purified recombinant extracellular domains of DC-SIGN and its homologue DC-SIGNR 
as tetramers comprising of the entire extra cellular domain including the α-helical 
neck region and monomers comprising of the carbohydrate recognition domain only. 
Direct binding studies revealed that both DC-SIGN and DC-SIGNR were able to bind 
independently to the recombinant globular head modules ghA, ghB, and ghC, with ghB 
being the preferential binder. C1q appeared to interact with DC-SIGN or DC-SIGNR 
in a manner similar to IgG. Mutational analysis using single amino acid substitutions 
within the globular head modules showed that TyrB175 and LysB136 were critical for the 
C1q–DC-SIGN/DC-SIGNR interaction. Competitive studies revealed that gC1qR and 
ghB shared overlapping binding sites on DC-SIGN, implying that HIV-1 transmission 
by DCs could be modulated due to the interplay of gC1qR-C1q with DC-SIGN. Since 
C1q, gC1qR, and DC-SIGN can individually bind HIV-1, we examined how C1q and 
gC1qR modulated HIV-1–DC-SIGN interaction in an infection assay. Here, we report, 
for the first time, that C1q suppressed DC-SIGN-mediated transfer of HIV-1 to activated 
pooled peripheral blood mononuclear cells, although the globular head modules did 
not. The protective effect of C1q was negated by the addition of gC1qR. In fact, gC1qR 
enhanced DC-SIGN-mediated HIV-1 transfer, suggesting its role in HIV-1 pathogenesis. 
Our results highlight the consequences of multiple innate immune pattern recognition 
molecules forming a complex that can modify their functions in a way, which may be 
advantageous for the pathogen.
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inTrODUcTiOn
Dendritic cell-specific intracellular adhesion grabbing non-
integrin (DC-SIGN) is a C-type lectin expressed on DCs that 
functions as a pattern recognition receptor (PRR). It can interact 
with a range of viral, bacterial, and fungal pathogens to primarily 
promote Th2 responses via activation of the mitogen-activated 
protein kinases Erk1 and Erk2 (1), leading to the clearance of 
pathogens. DC-SIGN also modulates TLR signalling by acti-
vating serine and threonine kinase Raf1, which acetylates the 
NF-κB subunit p65 upon interaction with pathogens, such as 
Mycobacterium tuberculosis, Mycobacterium leprae, Candida albi-
cans, and measles virus (2, 3). Acetylation of p65 and increased 
IL-10 transcription leads to an enhanced anti-inflammatory 
cytokine response (2). DC-SIGN also mediates DC–T cell inter-
action via intracellular adhesion molecule-3 (ICAM-3) (4). In 
addition, DCs can adhere to endothelial cells expressing high 
levels of ICAM-2 via DC-SIGN. Further interactions between 
lymphocyte function-associated antigen-1 (LFA-1) and ICAM-1 
with ICAM-2–DC-SIGN (5) promote trans-endothelial migra-
tion of DCs, allowing them to travel from the blood to the lym-
phatic system where they can induce T cell responses. Martinez 
et al. have shown that DC-SIGN stimulated CD3-activated T cells 
produce IL-2, which, in turn, enhances T cell differentiation (6). 
DC-SIGN can bind the cell wall component, glycolipid ManLAM 
of M. tuberculosis, and inhibit DC maturation through the 
suppression of TLR-4 (7). Such a cross talk between TLRs and 
DC-SIGN that generates anti-inflammatory immune response 
highlights the two-faced role of DC-SIGN in immune regulation.
DC-SIGN can bind to HIV-1 envelope protein gp120 through 
glycan structures (8) and mediate HIV transmission in cis and 
trans fashion. The cis mode supports DC-SIGN-mediated viral 
internalization and limited replication; in trans mode, viral 
particles are endocytosed and presented to CD4+ cells (9). 
DC-SIGN, thus, allows DCs to carry HIV-1 to the lymph nodes 
where interactions between DCs and T cells leads to transmis-
sion of the virus to CD4+ T cells, leading to their infection and 
eventual depletion (10). The hepatitis C virus (HCV) envelope 
glycoprotein E2 is another viral protein DC-SIGN engages with 
(11). This is achieved through utilizing its high quality endocytic 
capability to internalize the viral antigen, leading to the infection 
of DCs (12).
Structurally, DC-SIGN is composed of an extracellular domain 
(ECD), which exists as a tetramer, stabilized by an N-terminal 
α-helical neck region, followed by a carbohydrate recognition 
domain (CRD) (8). Its affinity for N-linked high mannose oli-
gosaccharides is evident through its ligands HIV-1 gp120 and 
ICAM-3 being highly glycosylated, indicating that this binding is 
mediated through the CRD region (13, 14). Studies have shown 
that the interaction between gp120 and DC-SIGN triggers a drop 
in IL-6 production by immature DCs. In addition, gp120 binding 
to DC-SIGN has also been shown to suppress the anti-apoptotic 
activity of Nef and induce apoptosis in immature DCs (14). Thus, 
HIV pathogenesis heavily relies on the interplay of molecular 
mechanisms involving DC-SIGN.
Recently, it has emerged that DC-SIGN interacts with the 
complement classical pathway recognition protein, C1q (15), in 
conjunction with its globular head receptor, gC1qR, on the sur-
face of immature DCs. C1q as well as gC1qR is known to associate 
with the viral envelope protein gp41 of HIV-1 (16, 17). C1q has 
been shown to interact with gp41 ectodomain via its globular 
head (gC1q) domain (18), specifically via the A chain (19), in 
a way similar to C1q–IgG interaction (20, 21). Similar to IgG, 
the ability of gp41 to form aggregates (16) leads to an enhanced 
activation of the C1 complex, as well as the function of gp41 to 
initiate the classical pathway on the surface of infected cells in 
an antibody-independent manner (22). The C1q binding site on 
gp41 resides within residues 601–613 of the immunodominant 
loop region (16), which contains hydrophobic side chains and 
forms a cleft (23).
gC1qR on its own has been shown to suppress the production 
of HIV-1 in MT-4 and H9 human T cell lines, and macrophages 
infected with HIV-1IIIB and HIV-1Ba-L (24) Suppression of virus 
production is further enhanced when gC1qR is preincubated 
with the target cell lines prior to HIV-1 challenge, suggesting that 
interference with viral entry by gC1qR occurs through interac-
tion with CD4 (24). gC1qR is known to bind to a range of viral 
ligands including the HCV core protein (25), adenovirus core 
protein V (26) EBNA-1 (27), and rubella virus capsid protein 
(28). gC1qR can also act as a receptor for HIV-1 gp41 and target 
healthy CD4+ T cells to natural killer (NK) cell-mediated lysis 
(17). This bystander effect of autologous killing occurs through 
the surface translocation of NKP44L, via activation of PI3K, 
NADPH oxidase, and p190 RhoGAP.
Recently, DC-SIGN, C1q, and gC1qR on immature DCs have 
been shown to form a tripartite complex, with a plausible role 
in DC differentiation through signaling via the NF-κB pathway 
(15). Given that each of these innate immune proteins (C1q, 
DC-SIGN, and gC1qR) can bind HIV-1, we set out to dissect the 
nature of interaction between C1q and DC-SIGN and examine 
how it can impact upon HIV-1 transmission.
MaTerials anD MeThODs
expression and Purification of soluble 
Dc-sign and Dc-signr
The pT5T constructs expressing tetrameric and monomeric 
forms of DC-SIGN and DC-SIGNR were transformed into 
Escherichia coli BL21 (λDE3) (8). Protein expression was 
performed using bacterial culture in Luria-Bertani medium 
containing 50 µg/mL of ampicillin at 37°C until OD600 reached 
0.7. The bacterial culture was induced with 10 mM isopropyl-
β-d-thiogalactoside (IPTG) and incubated for a further 3  h. 
Bacterial cells (1  L) were centrifuged at 4,500 ×  g for 15  min 
at 4°C and cell pellet was treated with 22  mL of lysis buffer 
containing 100 mM Tris, pH 7.5, 0.5 M NaCl, lysozyme (50 µg/
mL), 2.5 mM EDTA, pH 8.0, and 0.5 mM phenylmethylsulfonyl 
fluoride (PMSF), and left to stir for 1 h at 4°C. Cells were then 
sonicated for 10 cycles for 30  s with 2  min intervals and the 
sonicated suspension was spun at 10,000  g for 15  min at 4°C. 
The inclusion bodies, present in the pellet, were solubilized 
in 20  mL of 6  M urea, 10  mM Tris–HCl, pH 7.0, and 0.01% 
β-mercaptoethanol by rotating on a shaker for 1  h at 4°C. 
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The mixture was then centrifuged at 13,000 × g for 30 min at 
4°C, and the supernatant was drop-wise diluted fivefold with 
loading buffer containing 25 mM Tris–HCl pH 7.8, 1 M NaCl, 
and 2.5 mM CaCl2 with gentle stirring. This was then dialyzed 
against 2  L of loading buffer with three buffer changes every 
3 h. Following further centrifugation at 13,000 × g for 15 min at 
4°C, the supernatant was loaded onto a mannan-agarose column 
(5  mL; Sigma) pre-equilibrated with the loading buffer. The 
column was washed with five bed volumes of the loading buffer, 
and the bound protein was eluted in 1 mL fractions using the 
elution buffer containing 25 mM Tris–HCl pH 7.8, 1 M NaCl, 
and 2.5  mM EDTA. The absorbance was read at 280  nm, and 
the peak fractions were frozen at −20°C. Purity of protein was 
analyzed by 15% w/v SDS-PAGE.
expression and Purification of 
recombinant Wild-Type globular head 
Modules gha, ghB, and ghc of human 
c1q and Their substitution Mutants
The recombinant globular head regions of human C1q, ghA, 
ghB, and ghC modules (19) and their respective mutants (29) 
were expressed in E. coli BL21 as fusion to maltose-binding 
protein (MBP). Bacterial cells were grown in 200 mL LB medium 
containing ampicillin (100  µg/mL) at 37°C, and induced with 
0.4  mM IPTG at OD600 of 0.6 for 3  h, and then centrifuged 
(4,500 × g for 15 min). The cell pellet was suspended in 25 mL of 
lysis buffer (20 mM Tris–HCl pH 8.0, 0.5 M NaCl, 1 mM EDTA, 
0.2% v/v Tween 20, 5% glycerol, 0.1  mM PMSF, and 0.1  mg 
lysozyme) and incubated at 4°C for 1 h on a rotary shaker. Cell 
suspension was then sonicated for 30 s with 2 min gaps for 10 
cycles. After centrifugation (13,000 × g for 15 min), the super-
natant was diluted fivefold in buffer I (20 mM Tris–HCl, pH 8.0, 
100 mM NaCl, 0.2% Tween 20, 1 mM EDTA, and 5% glycerol), 
passed through an amylose resin column (15 mL; New England 
Biolabs), and then washed with three bed volumes of buffer I 
followed by buffer II (50 mL of buffer I without Tween 20). The 
protein was then eluted in 1 mL fractions with 10 mM maltose 
in 100 mL of buffer II and frozen at −20°C after determining 
protein concentration and purity via Nanodrop and 10% w/v 
SDS-PAGE, respectively.
Purification of human c1q from Plasma
C1q was purified from freshly thawed plasma as described previ-
ously (19). Briefly, plasma was made 5 mM EDTA, pH 7.5, and 
centrifuged to remove aggregated lipids. It was then incubated 
with non-immune IgG coupled to CNBr-activated Sepharose (GE 
Healthcare, UK) for 1 h at 4°C. The plasma with IgG-Sepharose 
was filtered through a sintered glass funnel, and C1q-bound 
Sepharose was then washed extensively with 10  mM HEPES, 
140 mM NaCl, 0.5 mM EDTA, pH 7.0. C1q was eluted with CAPS 
(N-cyclohexyl-3-aminopropanesulfonic acid) buffer (100  mM 
CAPS, 1 M NaCl, 0.5 mM EDTA, pH 11). The eluted C1q was 
then passed through a HiTrap protein G column (PierceNet, 
USA) to remove IgG contaminants and dialyzed against the 
washing buffer.
expression and Purification 
of human gc1qr
The recombinant mature gC1qR protein containing 74–282 
residues was expressed in E. coli BL21 (λDE3) (30). Bacterial cells 
were grown in 250 mL of LB at 37°C until an OD600 of 0.6 was 
reached and induced with 0.5 mM IPTG. After 3 h, the bacterial 
cell culture was spun down (4,500 g for 15 min). The cell pellet 
was treated with lysis buffer (20  mM Tris–HCl pH 8.0, 0.5  M 
NaCl, 1 mM EDTA, 0.2% Tween, 5% glycerol, 0.1 mg lysozyme) 
and incubated for 1 h at 4°C with shaking. The cell lysate was then 
sonicated for 10 cycles at 30  s with 2 min intervals. The lysate 
was spun down at 13,000 g for 15 min, and the supernatant was 
collected and dialyzed for 2 h against 20 mM Tris–HCl, pH 7.5. 
The dialyzed protein was subjected to ion exchange using a DEAE 
column and gC1qR eluted at a peak of 0.45 M NaCl.
Direct Binding elisa
Microtiter wells were coated overnight at 4°C with DC-SIGN or 
DC-SIGNR (5, 2.5, 1.25, and 0.625 µg/well) in carbonate–bicarbo-
nate buffer, pH 9.6, and left overnight at 4°C. Wells were blocked 
with 100 µL of 2% w/v BSA in PBS for 2 h at 37°C. Following three 
washes with PBS + 0.05% Tween 20, ghA, ghB, ghC, or its substi-
tution mutants (2.5 µg/100 μl) was added to each well in the buffer 
containing 50 mM NaCl, 100 mM Tris–HCl, pH 7.5, and 5 mM 
CaCl2. MBP (Sigma) was used as a negative control. The plate was 
incubated at 37°C for 1.5 h and then at 4°C for 1.5 h. The wells 
were washed and the bound protein was detected with anti-MBP 
monoclonal antibodies in PBS (1:5,000, Sigma) followed by rab-
bit anti-mouse IgG-HRP conjugate (1:5,000; Sigma) for 1 h. The 
color was developed using o-phenylenediamine dihydrochloride 
(OPD, Sigma) and read at 415 nm.
competitive elisa
DC-SIGN and DC-SIGNR proteins were coated on microtiter 
wells by overnight incubation at 4°C using 5 µg/well (in 100 µL) 
in  carbonate–bicarbonate buffer pH 9.6. Wells were blocked 
with 2% BSA in PBS for 2 h at 37°C. Following washing with 
PBS  +  0.05% Tween, the plate was incubated with a steady 
concentration (5  µg/well) of one competing protein (gC1qR) 
and various concentrations (5,  2.5, 1.25, 0.625  µg/well) of the 
second competing protein (ghB) in calcium buffer to give a total 
of 100 µL/well. After incubating for 1.5 h at 37°C and 1.5 h at 
4°C, the wells were washed and anti-gC1qR polyclonal antibody 
(1:1,000) in PBS was added and incubated for a further 1 h at 
37°C. Bound protein was detected by Protein A-HRP conjugate 
(1:5,000), and the color was developed using OPD. Data were 
plotted to determine inhibition values of competitive ligand 
binding.
In order to examine if C1q and globular head modules can 
inhibit binding of DC-SIGN to gp120, microtiter wells were 
coated with 250 ng of gp120 (Abcam) in carbonate–bicarbonate 
buffer and left overnight at 4°C. Plate was blocked with 2% w/v 
BSA in PBS for 2 h at 37°C, followed by washing three times 
with PBS +  0.05% Tween 20. Various concentration of ghA, 
ghB, ghC, and C1q (10, 5, 2.5, 0 µg/mL) were co-mixed with 
2.5  µg/mL of DC-SIGN and added to wells in calcium buffer 
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(100 µL/well). After incubation for 1 h at 37°C and 1 h at 4°C, the 
wells were washed again three times using PBS + 0.05% Tween 
20. The binding of DC-SIGN to gp120 in the presence of globular 
heads and C1q was detected using rabbit anti-DC-SIGN antibody 
(1:500) and probed with Protein A-HRP conjugate (1:5,000). The 
color was developed using 3,3′,5,5′-tetramethylbenzidine (TMB) 
and read at 450 nm spectrophotometrically.
Western Blotting
Recombinant ghA, ghB, and ghC modules (15 µg), in addition to 
MBP and BSA as negative control proteins, were run separately 
on a 12% SDS-PAGE gel and transferred onto PDVF membrane 
for 1 h at 320 mA. Membrane was blocked in 5% non-fat milk 
(1 h at room temperature) and 50 µg of recombinant DC-SIGN 
(tetramer) in loading buffer (25 mM Tris–HCl, pH 7.8, 1 M NaCl, 
2.5  mM CaCl2) was added and incubated overnight at room 
temperature. The blot was washed three times for 10 min each in 
PBS containing 0.05% Tween 20 and then incubated with anti-
DC-SIGN (1:1,000) polyclonal antibody (ProSci) in 1% non-fat 
milk (2 h at 37°C). Following subsequent washes, the membrane 
was incubated with Protein A-conjugated HRP (1:1,000) (1 h at 
room temperature). The blot was developed using 3, 3′-diamin-
obenzidine (DAB; Sigma D7679) as a substrate.
Fluorescent Microscopy
Binding of C1q Globular Head Modules  
to DC-SIGN Expressed on HEK Cells
DC-SIGN-expressing HEK 293 (DC-HEK) cells, as reported by 
Lang et al. (31) were grown in DMEM-F12 (Life Technologies, 
UK) containing 10% v/v FCS and blasticidin (5 µg/mL) (Gibco). 
The cells were grown on 13 mm glass cover slips till a monolayer 
of cells was formed and then incubated with 15 µg/mL of recom-
binant ghA, ghB, and ghC (MBP as a negative control) separately 
in serum free medium and left to incubate for 30 min in 37°C. 
Cells were washed with PBS and fixed using 4% v/v paraformal-
dehyde for 10 min, rinsed again with PBS three times, and then 
blocked with 5% FCS for 30 min. The slides were incubated for 
30  min with mouse anti-MBP antibody to detect MBP fusion 
proteins and rabbit anti-DC-SIGN antibody to reveal expression 
of DC-SIGN in DC-HEK cells. After three washes for 30  min 
each and incubation with secondary antibodies: Alexa Fluor 
568 conjugated goat anti-mouse antibody (Thermo Fisher) and 
Alexa Fluor 488 conjugated goat anti-rabbit antibody (Abcam) 
for 30 min, the slides were then washed in PBS, mounted, and 
observed under Leica DM4000 Fluorescent microscope using 
Leica Application Suite.
HIV-1 Transfer Assay with DC-HEK Cells and Pooled 
Peripheral Blood Mononuclear Cell (PBMC)
Pooled peripheral blood mononuclear cells (HiMedia Labo-
ratories, India) were cultured in RPMI 1640 medium (Sigma 
Aldrich) containing 10% FBS, 1% Penicillin–Streptomycin 
(Complete RPMI medium), and stimulated with 5 µg/mL phyto-
hemaglutinin (PHA) and 10 U/Ml of recombinant-human IL-2 
(Gibco) for 24 h. PHA/IL-2 was washed off and activated PBMCs 
were cultured further for 3 days in complete RPMI 1640 medium.
DC-HEK cells were grown and maintained in DMEM-F12 
(Sigma-Aldrich, USA) containing 10% FBS and blasticidin (5 µg/
mL) (Gibco). Cells were sub-cultured every 3 days and those in 
the log phase were used for assays. DC-HEK cells were grown in 
a 12 well plate until 80% confluence. Indicated concentrations of 
C1q, ghA, ghB, ghC, and gC1qR individually, or in combination, 
in medium containing 5 mM CaCl2 were added to each well and 
incubated for 2 h to allow binding. Excess protein was removed 
and cells were challenged with 5  ng/mL p24 of HIV-1 SF-162 
strain (kindly provided by Dr. Jay Levy, NIH AIDS Program, 
National Institutes of Health, USA) for 1  h. MBP was added 
along with the virus as a negative protein control. Unbound 
virus was washed off and cells were co-cultured with PHA/IL-2 
activated PBMCs for 24 h to facilitate viral transfer. PBMCs in 
the supernatant were then separated from the adhered DC-HEK 
monolayer and cultured further for 7  days and viral titer was 
determined using HIV-1 p24 antigen ELISA of supernatants 
collected on days 4 and 7 (XpressBio Life Science Products, 
Frederick, MD, USA). That the reduction in p24 levels was not 
due to cellular death was confirmed by MTT assay of cultured 
PBMCs on day 7.
statistical analysis
Viral transfer experiment data were plotted using GraphPad 
Prism version 5.0, and analyzed for statistical significance 
using one-way ANOVA. P < 0.05 was considered as statistically 
significant.
resUlTs
Both Dc-sign and Dc-signr Bind to c1q
DC-SIGN and DC-SIGNR comprising of the entire ECD 
(Figures 1A,C) and the CRD region alone (Figures 1B,D) were 
expressed in E. coli and affinity-purified on mannose-agarose. 
The CRD regions of DC-SIGN and DC-SIGNR bound mannose 
weakly as majority of the proteins appeared in the flow through. 
The ECD domains of both DC-SIGN and DC-SIGNR bound 
to mannose with much greater affinity in the presence of Ca2+ 
and eluted with EDTA. Previously, Kang et al. have shown that 
DC-SIGNR interacts with C1q (32). Recently, work by Hosszu 
et al. revealed that DC-SIGN bound directly to C1q (15). Thus, we 
examined direct binding of both the tetrameric and monomeric 
variants of DC-SIGN and DC-SIGNR with purified human C1q 
on microtiter plates. Both DC-SIGN (Figure 2A) and DC-SIGNR 
(Figure 3A) in their tetrameric and monomeric forms were able 
to bind to C1q in a dose-dependent manner. Experiment showed 
a strong binding of the tetramers to C1q when compared to the 
CRD region alone, with the ability of C1q to bind nearly 50% more 
when the α-helical neck was intact. C1q bound to DC-SIGNR 
(Figure 3A) better than DC-SIGN (Figure 2A). The ability of the 
globular head modules to bind DC-SIGN was also examined via 
a far-western blot (Figure 2D), where ghA, ghB, and ghC, run on 
a SDS-PAGE and transferred on a nitrocellulose membrane, were 
probed with soluble DC-SIGN tetramer. ghA and ghB appeared to 
bind DC-SIGN well compared to the ghC module. MBP and BSA, 
used as negative control proteins, did not bind DC-SIGN tetramer.
FigUre 1 | sDs-Page under reducing conditions (12% v/v) 
showing purified fractions of soluble Dc-sign tetramer (a), 
Dc-sign monomer (B), Dc-signr tetramer (c), and Dc-signr 
monomer (D), following purification by mannose-agarose affinity 
chromatography.
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Dc-sign and Dc-signr neck region is 
required for efficient Binding to c1q 
and individual globular head Modules
Tetrameric (Figure 2B) and monomeric (Figure 2C) DC-SIGN 
and DC-SIGNR (Figures  3B,C) coated on microtiter wells 
were probed with ghA, ghB, and ghC to examine whether these 
globular head modules were able to bind to the ECD and CRD 
with similar avidity. ghA, ghB, and ghC bound with much 
greater affinity to DC-SIGN and DC-SIGNR tetramer in com-
parison to the monomers, indicating that the neck is required 
for the individual globular heads to bind efficiently. Like C1q, 
the ghA, ghB, and ghC modules bound DC-SIGNR better than 
DC-SIGN (Figure 3B).
Dc-sign and Dc-signr Bind 
Preferentially to ghB Module
Since C1q bound to DC-SIGN and DC-SIGNR via its globular 
head region, as evident from the use of ghA, ghB and ghC modules, 
we sought to map their specificity for DC-SIGN and DC-SIGNR 
binding (Figures 2B and 3B). When DC-SIGN and DC-SIGNR 
were coated on microtiter wells and probed with ghA, ghB, and 
ghC, all three globular heads bounds DC-SIGN and DC-SIGNR 
in a dose-dependent manner, indicating that all three heads are 
capable of binding to the ligands independently. Furthermore, 
ghB module was preferential in binding to DC-SIGN (Figure 2B); 
it bound much better to DC-SIGN compared to ghA and ghC. In 
addition, ghB was a better binder of DC-SIGNR, as was ghA for 
DC-SIGNR (Figure 3B) than DC-SIGN (Figure 2B), compared 
with the ghC module. Although binding of ghA, ghB, and ghC 
to the CRD domain was significantly lower, the ghB module was 
still a better binder of DC-SIGN (Figure  2C) and DC-SIGNR 
(Figure 3C) monomers.
The gha substitution Mutants Bind 
Differentially to Dc-sign and Dc-signr
The ability of substitution mutants ArgA162Glu and ArgA162Ala 
to bind to DC-SIGN and DC-SIGNR was assessed by ELISA. 
Both substitution mutants bound DC-SIGN (Figure  4A) and 
DC-SIGNR (Figure 5A) in a dose-dependent manner. DC-SIGNR 
was able to interact with ArgA162Glu nearly as efficiently as it did 
with the wild-type ghA, showing a reduction in binding of only 
15% at the highest concentration of 5 µg (Figure 5A). ArgA162Ala, 
on the other hand, bound DC-SIGNR with much less affinity, 
showing a drop of 27% (Figure  5A). Considering DC-SIGN 
and DC-SIGNR are both highly conserved, ArgA162Glu was able 
to interact with DC-SIGN weakly than it did with DC-SIGNR 
(Figures  4A and 5A), showing a ~35% reduced binding as 
opposed to ~5% (seen with DC-SIGNR.) The mutant ArgA162Ala 
bound DC-SIGN in a similar manner as it did to its homologue 
DC-SIGNR showing a reduced binding of ~25% (Figure 4A).
ghB substitution Mutants Bind 
Differentially to Dc-sign and Dc-signr
Using ELISA, we examined the ability of DC-SIGN to bind to the 
ghB substitution mutants ArgB114Gln, ArgB114Ala, ArgB163Glu, 
ArgB163Ala, ArgB129Ala, ArgB129Glu, HisB117Asp, TyrB175Leu, 
and LeuB136Gly (29). All the ghB substitution mutants bound 
DC-SIGN (Figure 4B) and DC-SIGNR (Figure 5B) in a dose-
dependent manner. Substituting ArgB114 to Gln and Ala resulted 
in a reduction of ~50% in the case of DC-SIGN (Figure 4B) and 
DC-SIGNR binding (Figure 5B), suggesting that the Arg residue 
at this position plays an important role in the C1q–DC-SIGN/
DC-SIGNR interaction (Tables 1 and 2).
Substituting the ghB mutant ArgB129 with Glu and Ala caused 
a slight reduction of ~20% binding with DC-SIGN (Figure 4B) 
and up to ~40% with DC-SIGNR (Figure  5B). When ArgB163 
was replaced with the negatively charged Glu, its affinity for 
DC-SIGN and DC-SIGNR was reduced by 50 and 35%, respec-
tively (Figures 4B and 5B) (Tables 1 and 2); substitution with Ala 
resulted in 30% reduction for DC-SIGN (Figure 4B) and increase 
by 20% for DC-SIGNR (Figure 5B) (Tables 1 and 2). A greater 
reduction in DC-SIGN and DC-SIGNR binding of ~60% was 
observed for the ghB mutant HisB117 substituted for Asp. For the 
ghB module, TyrB175 substitution to Leu had the most significant 
effect, showing a dramatic decrease of up to 90% in binding to 
DC-SIGN as well as DC-SIGNR at a concentration of 0.625 µg; 
this is not surprising due to its role in stabilizing the gC1q domain.
FigUre 2 | interaction of c1q, gha, ghB, and ghc with Dc-sign tetramer and monomer. (a) Microtiter wells coated with different concentrations (5, 2.5, 
1.25, 0.625 µg/well) of DC-SIGN tetramer or monomer were probed with 2 µg/well of C1q. Bound C1q was detected with anti-C1q polyclonal antibodies (1:1,000 in 
PBS) and Protein A HRP conjugate (1:1,000 in PBS). BSA was used as a negative control protein. (B) Binding of ghA, ghB, and ghC to DC-SIGN tetramer and (c) 
DC-SIGN monomer involved coating a range of concentrations of the respective proteins on microtiter wells, which were then incubated with a fixed concentration 
of ghA, ghB, ghC, and MBP (2.5 µg/well in 5 mM CaCl2 buffer) at 37°C. Binding was detected using anti-MBP monoclonal antibodies (1:5,000 in PBS) and then 
rabbit anti-mouse IgG-HRP (1:5,000 in PBS). (D) Far western blot to show DC-SIGN tetramer binding to membrane-bound ghA, ghB, and ghC: 15 µg of ghA, ghB, 
and ghC (BSA and MBP as negative control proteins) were run on a 12% SDS-PAGE gel and then transferred on to nitrocellulose membrane. The blot was 
incubated with 50 µg of DC-SIGN in PBS overnight at room temperature. The bound DC-SIGN protein was detected using anti-DC-SIGN polyclonal antibodies and 
Protein A HRP conjugate. Bands were developed using diaminobenzidine tablets dissolved in water.
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residue leu136 on ghB, important  
for igg Binding, is also involved  
in Dc-sign Binding
Using a series of globular head single residue substitution mutants 
(29), we sought to examine that residues in the ghB chain offered 
complementary binding sites for DC-SIGN. Since LeuB136 and 
TyrB175 residues are considered important in maintaining the gC1q 
structure as well as for IgG binding (33), we used LeuB136 substi-
tuted for Glu and TyrB175 substituted for Leu in direct-binding 
ELISA. LeuB136Gly showed ~50% less binding to DC-SIGN at the 
highest concentration (Figure 4B), suggesting that DC-SIGN and 
IgG binding sites on C1q (ghB) are overlapping.
The contributions of ghc substitution 
Mutants to Dc-sign Binding
The substitution mutants His101Ala, Arg156Glu, and Leu170Glu 
bound to DC-SIGN in a dose-dependent manner (Figure 4C). In 
fact, replacing Leu170 with Glu of the ghC chain reduced binding to 
DC-SIGN with a decrease in ~25% at the highest concentration. 
The ghC mutants His101Ala reduced binding by 10%, suggesting 
that the contributions of His101 and Leu170 are comparable in the 
DC-SIGN–C1q interaction. The ghC substitution mutants also 
bound to DC-SIGNR in a dose-dependent manner.
The mutants His101Ala appeared to show ~10% better binding 
to DC-SIGNR with compared to wild type, whereas Leu170Glu 
and Arg156Glu showed reduced binding by up to 25% at the 
highest concentration of 5 µg of DC-SIGNR (Figure 5C; Table 2).
gc1qr and ghB compete for the same 
Binding site on Dc-sign
In view of the recent report of gC1qR, C1q, and DC-SIGN form-
ing a trimeric complex on immature DCs (15), we examined 
whether DC-SIGN has complementary and overlapping binding 
site for C1q and gC1qR. We have recently mapped the gC1qR 
binding site on ghA, ghB, and ghC (30). Since ghB was found 
to be the preferential binder of DC-SIGN, ghB modules were 
tested in a competitive assay. When different concentrations of 
ghB and a constant concentration of gC1qR were challenged 
against DC-SIGN, probing with anti-gC1qR polyclonal antibody 
revealed that with decreasing concentration of ghB, more gC1qR 
was able to bind to solid-phase DC-SIGN (Figure 6A), thereby 
FigUre 3 | interaction of c1q, gha, ghB, and ghc with Dc-signr tetramer and monomer. (a) ELISA to examine binding of C1q to DC-SIGNR tetramer 
and SIGN-R monomer: DC-SIGNR tetramer or monomer were coated at different concentrations, followed by addition of 2 µg/well of C1q. Bound C1q was probed 
with anti-C1q polyclonal antibodies (1:1,000 in PBS) and Protein A HRP (1:1,000 in PBS), and the color was developed using o-phenylenediamine dihydrochloride.  
(B) Binding of ghA, ghB, and ghC to DC-SIGNR tetramer and (c) SIGN-R monomer: different concentrations of DC-SIGNR tetramer (B) and DC-SIGNR monomer 
(c) were coated on microtiter wells in carbonate buffer and incubated overnight at 4°C and then incubated with ghA, ghB, ghC, and MBP (2.5 µg/well in 5 mM 
CaCl2 buffer). Binding was detected using anti-MBP monoclonal antibody and rabbit anti-mouse IgG-HRP conjugate.
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implying an overlapping binding site between the proteins. 5 µg 
of DC-SIGN and 5  µg of gC1qR were able to bind efficiently, 
showing an OD of 1 (data not shown); this binding appeared 
to be drastically reduced when 5  µg of gC1qR was allowed to 
compete with 5 µg of ghB.
c1q, gha, ghB, and ghc inhibit the Binding 
of Dc-sign to gp120
C1q, ghA, ghB, and ghC were able to inhibit the binding of 
DC-SIGN to immobilized gp120 in a dose-dependent manner. 
The highest concentration of C1q, ghA, ghB, and ghC were able to 
significantly compete out the binding of DC-SIGN (Figure 6B).
The gha, ghB, and ghc Modules Bind to 
cell surface-expressed Dc-sign
The binding of globular head modules to DC-SIGN was also 
performed using HEK 293 cells expressing DC-SIGN on the 
cell surface. The surface expression of DC-SIGN on DC-HEK 
cells was first confirmed with antibodies against DC-SIGN. To 
confirm the binding of individual globular head modules to 
DC-SIGN on DC-HEK cells, ghA, ghB, and ghC fused with MBP 
were added to the DC-HEK cells (Figure 7). Incubation of the 
globular head modules and probing with anti-MBP monoclonal 
antibodies showed that each globular head module bound on the 
surface of DC-HEK cells co-localizing with DC-SIGN expressed 
on DC-HEK cells unlike MBP (Figure 7).
c1q inhibits Dc-sign-Mediated Transfer 
of hiV-1 to PBMc in culture
Since CD4+ T cells and macrophages are the main cells targeted 
by HIV-1, we looked at the potential of C1q, ghA, ghB, ghC, 
and gC1qR to modulate DC-SING-mediated transfer of HIV-1 
to activated PMBCs. As shown in Figure 8A, C1q considerably 
inhibited viral transfer to PBMCs in a dose-dependent manner 
on days 4 and 7. The globular head modules, ghA, ghB, and ghC, 
surprisingly did not interfere with HIV-1 transfer, neither indi-
vidually nor collectively, when compared to untreated or MBP-
treated control, suggesting that the collagen region of C1q and/or 
its multivalency of the gC1q domains are likely requirement for 
enforcing inhibitory properties. Addition of MBP in the control 
wells did not significantly affect the p24 levels in comparison 
with untreated controls (data not shown). Furthermore, during 
the assay period, cellular viability was not affected by any of the 
protein treatments, suggesting that differences in the infectivity 
were not due to cell death (data not shown).
We further examined the involvement of gC1qR with 
DC-SIGN in HIV-1 infection transmission (Figure 8B). gC1qR 
has previously been shown to inhibit CD4–gp120 interaction 
in HIV-1 isolates. It has also been recognized as a receptor on 
CD4+ T cells that gp41 engages with in order to cause death of 
bystander CD4+ T cells. We wanted to determine the role of 
gC1qR in DC-SIGN-mediated infection with or without C1q. 
Figure 8B shows that gC1qR alone did not mediate viral transfer 
FigUre 4 | Binding of globular head substitution mutants to Dc-sign. Different concentrations of DC-SIGN tetramer were coated on microtiter wells in 
carbonate buffer overnight at 4°C. Wells were then incubated with 2.5 µg/well (in CaCl2) of recombinant globular head wild type and mutant proteins and probed 
with anti-MBP monoclonal antibody and rabbit anti-mouse IgG-HRP conjugate. Percent binding was calculated for each mutant using binding of the wild-type 
globular head module as 100%. (a) Binding of ghA, ghA-R162E, and ghA-R162A to DC-SIGN; (B) binding of ghB mutants ghB-L136G, ghB-T175L, ghB-R114Q, 
ghB-R114A, ghB-R163A, ghB-R163E, ghB-R129E, ghB-R129A, and ghB-H117D to DC-SIGN; (c) binding of ghC mutants ghC-R156E, ghC-L170E, and 
ghC-H101A to DC-SIGN.
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through DC-SIGN but significantly promoted viral transfer in 
the presence of C1q as well as the three globular head modules 
together for up to 7 days. This suggests that the tripartite interac-
tion between C1q, gC1qR, and DC-SIGN enhances DC-SIGN-
mediated viral transfer. Thus, association of these proteins on 
DCs may actually promote HIV-1 infection. In addition, involve-
ment of gC1qR in the tripartite complex is likely to negate the 
protective effect of C1q.
DiscUssiOn
The role of complement in HIV-1 pathogenesis is well-docu-
mented. Complement-opsonized HIV-1 causes enhanced viral 
infection of CD4+ T cell lines (34), PBMCs, monocytes, and 
macrophages (35). DC-SIGN on the surface of immature DCs 
is involved in the capture of C3 opsonized R5 and X4 tropic 
HIV-1 and enhanced transmission to T cells (36). C1q can bind 
to gp41 directly in an antibody-independent manner and activate 
the classical pathway (16); however, this leads to an enhanced 
infection of complement receptor-bearing cells (37). To escape 
complement-mediated destruction, HIV-1 uses follicular DCs 
as a viral reservoir (38), following its internalization via CR2, 
and remains within its protective recycling endosome. Following 
emergence from the endosome to the cell surface, HIV-1 infects 
follicular T cells through CD4. HIV-1 opsonized with C3b 
interacts with CR1 on erythrocytes with factor I dissociating 
erythrocytes from this complex and converting C3b to iC3b and 
C3d. C3d opsonized HIV-1 is then able to bind to CR2 on B cells 
(39). In this study, we have examined complement-independent 
interaction of C1q with HIV-1 via DC-SIGN.
C1q is a charge pattern recognition protein that binds to a 
variety of ligands via its gC1q domain (19). Following its ability to 
interact with DC-SIGNR (32), Hosszu et al. recently have shown 
that C1q also recognizes a peptide derived from its homolog 
DC-SIGN (15). In the current study, we made use of the avail-
ability of recombinant individual globular head modules of C1q 
(ghA, ghB, and ghC) and its substitution mutants to establish that 
C1q binds DC-SIGN (and DC-SIGNR) via its gC1q domain.
Structure-function studies have demonstrated that the CRD 
region of DC-SIGN is the specific site for ligand binding and only 
funcions in the presence of the neck region within the ECD (12). 
We performed a series of binding experiments involving both 
the tetrameric forms of DC-SIGN and DC-SIGNR (comprising 
of the ECD and CRD region) as well as the monomeric forms, 
which only consist of the CRD region. We asked the question 
whether DC-SIGN and DC-SIGNR binding sites for C1q (and its 
gC1q domain) lies within their CRD region, or the α-helical neck 
region also plays an important role in these interactions. Both 
proteins have an increased affinity for glycoproteins containing 
high mannose oligosaccharides, such as mannan (40), gp120 (10), 
and ICAM-3 (41), via the CRD region. Here, individual globular 
head modules bound better to the tetrameric forms of DC-SIGN 
TaBle 2 | Bindings of globular head modules and its mutants with 
Dc-signr (% binding ± sD).
ghA 100.00 ± 0.00
 R162E 94.78 ± 15.08
 R162A 73.17 ± 9.54
ghB 100.00 ± 0.00
 R129E 136.70 ± 21.82
 R163A 119.68 ± 30.09
 R129A 92.55 ± 2.26
 R163E 65.69 ± 4.89
 R114A 61.44 ± 0.38
 L136G 53.99 ± 1.88
 R114Q 50.27 ± 3.39
 H117D 40.96 ± 2.26
 T175L 37.23 ± 1.50
ghC 100.00 ± 0.00
 H101A 112.60 ± 2.86
 L170E 79.81 ± 20.40
 R156E 75.77 ± 4.62
TaBle 1 | Bindings of globular head modules and its mutants with 
Dc-sign (% binding ± sD).
ghA 100.00 ± 0.0
 R162A 77.71 ± 8.85
 R162E 66.41 ± 2.38
ghB 100.0 ± 23.62
 R129E 93.91 ± 8.34
 R129A 75.05 ± 7.22
 R163A 68.76 ± 12.78
 R114A 57.37 ± 4.45
 R114Q 52.46 ± 1.94
 R163E 48.33 ± 8.89
 L136G 47.74 ± 9.17
 T175L 37.92 ± 7.50
 H117D 36.35 ± 10.28
ghC 100.00 ± 0.00
 R156E 101.41 ± 0.27
 H101A 90.20 ± 2.27
 L170E 78.32 ± 1.47
FigUre 5 | Binding of globular head substitution mutants to Dc-signr. Different concentrations of DC-SIGNR tetramer were coated on microtiter wells in 
carbonate buffer overnight at 4°C and then incubated with 2.5 µg/well of recombinant globular head wild type and mutant proteins and probed with anti-MBP 
monoclonal antibody and rabbit anti-mouse IgG-HRP conjugate. Percent binding was calculated for each mutant using binding of the wild-type globular head 
module as 100%. (a) Binding of ghA, ghA-R162E and ghA-R162A to DC-SIGNR; (B) binding of ghB mutants ghB-L136G, ghB-T175L, ghB-R114Q, ghB-R114A, 
ghB-R163A, ghB-R163E, ghB-R129E, ghB-R129A, and ghB-H117D to DC-SIGNR; (c) binding of ghC mutants ghC-R156E, ghC-L170E, and ghC-H101A to 
DC-SIGNR.
9
Pednekar et al. C1q and DC-SIGN in HIV-1 Pathogenesis
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 600
and DC-SIGNR as opposed to just the CRD region alone, indicat-
ing that the neck region, and hence, multimerization is needed 
to facilitate C1q binding. The neck region of DC-SIGN and 
DC-SIGNR interestingly differ most in their α helical structures 
(8) as the 23 amino acid repeats only show the first half of each 
repeat presenting a pattern of hydrophobic residues spaced at 
intervals, a feature that is abundant in most dimeric and trimeric 
coiled-coils (42).
We also found that the ghB module bound better to DC-SIGN 
and DC-SIGNR. Previous studies have identified ghB as a key 
module of the gC1q domain in binding to IgG, PTX3, and 
CRP (43, 44). Interestingly, C1q and ghB bound DC-SIGNR 
better than DC-SIGN, despite 77% sequence similarity. We also 
expressed and purified globular head mutants (29) where single 
amino acid residues were substituted in order to localize key 
residues involved in C1q interaction with its various ligands. 
These mutants were designed based on the crystal structure and 
are the residues known to be important in binding to various 
C1q ligands (43). It appears that IgG and DC-SIGN binding 
sites on ghB are overlapping and shared, including Lys136 and 
FigUre 6 | competitive inhibition of Dc-sign: hiV-1 gp120 interaction by globular head modules and gc1qr. (a) ELISA to assess whether gC1qR and 
ghB directly compete for the same binding site on DC-SIGN: DC-SIGN was coated at 5 µg/well overnight at 4°C. Wells were blocked with 2% BSA in PBS for 2 h at 
37°C. gC1qR (5 µg/well) and different concentrations of ghB (5, 2.5, 1.25, 0.625 µg/well) were added in buffer containing 5 mM CaCl2. Incubation was carried out at 
37°C for 1.5 h and 4°C for 1.5 h. Following repeated washes, bound gC1qR was probed using rabbit anti-gC1qR polyclonal antibodies (1:1,000) and Protein 
A-HRP (1:1,000). Color was developed using o-phenylenediamine dihydrochloride substrate; (B) competition between DC-SIGN tetramer and C1q globular head 
modules to bind solid-phase gp120. Microtiter wells were coated with 250 ng of gp120. Various concentrations of ghA, ghB, ghC, and C1q and constant 2.5 µg/mL 
of DC-SIGN were incubated at 37°C for 1 h and then at 4°C for 1 h. The binding of DC-SIGN to gp120 in the presence of globular heads or C1q was detected 
using rabbit anti-DC antibody (1:500), probed with Protein A HRP (1:5,000). DC-SIGN alone binding to gp120 was used as 100%.
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Tyr175 on ghB, which have been previously shown to be impor-
tant for binding to IgG (29) and for gC1q assembly (45). We 
also examined the roles of Arg114, Arg129, and Arg163 of the ghB 
module since arginine residues have previously been shown 
to be important for the C1q–IgG interaction (46). Moreover, 
Hosszu et  al. have reported that C1q binds DC-SIGN via its 
IgG binding site  (15). Our results highlighted the significance 
of Arg114 in C1q  interaction with DC-SIGN and DC-SIGNR 
(Figures 4B and 5B). Substituting Arg114 with the polar residue 
Glutamine and hydrophobic residue Ala led to ~80% reduction, 
highlighting a very important role for Arginine114 of B chain in 
C1q–DC-SIGN interaction. In addition, Tyr175 appears critical 
for C1q interaction with DC-SIGN and DC-SIGNR (Figures 4B 
and 5B); the binding analysis revealed a dramatic reduction 
(82% for DC-SIGN and 90% for DC-SIGNR following substitu-
tion of Tyr with Leu). This is not the first time Tyr175 has been 
shown to be a critical residue in gC1q binding (33). Gadjeva et al. 
have shown that this residue mainly constitutes C1q binding to 
FigUre 7 | In vitro binding of globular heads modules to Dc-sign expressed on heK cells. DC-SIGN-expressing HEK cells (DC-HEK cells) were incubated 
with recombinant globular head modules (ghA, ghB, ghC) and MBP as control for 30 min at 37°C. DC-HEK cells were fixed with 4% paraformaldehyde, washed and 
blocked with 5% FCS, and probed with mouse anti MBP antibody to detect the presence of MBP fused globular head modules and rabbit anti DC-SIGN to detect 
DC-SIGN expressed on the cells. Goat anti-mouse secondary antibody conjugated with Alexa Fluor 568 was used to detect binding of globular heads whereas 
DC-SIGN expression was visualized using goat anti-rabbit IgG conjugated with Alexa Fluor 488 antibody. Scale bar 20 µm.
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IgM. Overall, our binding studies suggest that Tyr175 and Arg114 
of ghB are critical for the C1q–DC-SIGN and C1q–DC-SIGNR 
interaction.
The known dual roles of DC-SIGN as a facilitator of adap-
tive immune response as well as promoter of HIV-1 infection 
prompted us to examine if innate immune soluble factors such 
as C1q and gC1qR can potentially modulate viral transmission 
via DC-SIGN (47), similar to reports involving CD4+ T cells 
(48) and a lectin drug GRFT (Griffithsia) isolated from the red 
algae (49). We also included DC-SIGNR (DC-SIGN-related), a 
homolog of DC-SIGN, in our study. DC-SIGN-R is expressed 
on endothelium including liver sinusoidal (50), lymph node 
sinuses, and placental capillary (8). DC-SIGNR can bind 
ICAM-3 as well as gp120 to facilitate HIV-1 viral infection 
(50). As a receptor for bacterial dextrans (51) and capsular 
pneumococcal polysaccharide of Streptococcus pneumoniae, 
DC-SIGN-R can cause proteolysis of C3 (32). DC-SIGN-R is 
shown to be highly expressed by spleen marginal zone mac-
rophages (MZM) and lymph node macrophages (52). SIGN-R1 
(mouse homologue) in MZM interacts with C1q in the spleen 
and enhances apoptotic cell clearance via activation of the clas-
sical pathway (53).
The transmembrane envelope gp41 protein of HIV-1 is 
known to interact with C1q (54) through its A chain (19), lead-
ing to complement activation but no viral lysis (55). Instead, 
the virus is transmitted to complement receptor bearing cells 
such as macrophages and CD4+ T cells allowing infection to 
take place (37, 54, 56, 57). HIV-1-infected CD4+ T cells can 
activate the classical pathway via shedding of gp120, leading to 
unmasking of the gp41 epitope 601–613 available for interaction 
AB
FigUre 8 | hiV transfer assay mediated by Dc-sign. Cell surface DC-SIGN expressing HEK (DC-HEK) cells were grown in a 12-well plate to form a confluent 
layer. Different concentrations of proteins were added to the cells and incubated for 2 h for binding. Unbound proteins were removed and cells were challenged with 
2.5 ng/mL p24 of HIV-1 (SF-162 strain) for 1 h. Unbound virus was washed off and cells were co-cultured with PHA-activated PBMCs for 24 h. PBMCs were 
separated from the DC-HEK monolayer and cultured separately for 7 days to determine viral titer of the supernatants collected on days 4 and 7. (a) C1q, ghA, ghB, 
ghC, and ghABC; (B) gC1qR in presence of C1q, ghA, ghB, ghC, and ghABC. Data represent mean ± SD. P < 0.05 is considered significant. * and # indicate 
statistical significance in comparison to untreated controls of days 4 and 7, respectively.
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with C1q (23). C1q is also involved in a range of processes 
independent to its complement functions (58, 59), including DC 
differentiation (60). C1q, along with its globular head receptor 
gC1qR and DC-SIGN, can co-localize on the surface of blood 
precursor DCs to promote DC differentiation (15). gC1qR, a 
multifunctional pathogen recognition receptor (61, 62), can also 
interact with gp41 of HIV-1 (17) on uninfected CD4+ T cells and 
upregulate NK cell ligand NKP44-L, rendering healthy CD4+ T 
cells susceptible to NK cell lysis. Since DC-SIGN is a receptor 
for HIV-1 through its binding to gp120, it is interesting that it 
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co-localizes with C1q and gC1qR, the two proteins, also known 
for HIV-1 binding and transmission of the viral infection. Such 
association forming a trimolecular unit on the target cell surface 
may create a vehicle that promotes pathogen entry and immu-
nosuppression (15).
We wanted to examine if C1q–DC-SIGN interaction modulated 
HIV-1 transfer. We found that full length C1q but not its individual 
globular heads, suppressed DC-SIGN-mediated HIV-1 transfer 
to activated PBMCs. Curiously, addition of gC1qR negated the 
protective effects of C1q by enhancing DC-SIGN-mediated viral 
transfer. gC1qR, as an inhibitor of HIV-1 infection, can block 
the interaction between CD4 and gp120 and prevent viral entry 
(24). Since DC-SIGN binds to gp120 and gC1qR to gp41, both 
promoting infection, we can consider that even if gC1qR does 
interfere with the DC-SIGN-gp120 interaction, its active binding 
site for gp41 is still available to facilitate infection. The increased 
viral transmission of gC1qR seen when in association with C1q 
suggests that C1q bound to gC1qR can enhance its function. It 
is possible that C1q plays a protective role by blocking access of 
gp120 to DC-SIGN (Figure  9). This can happen if C1q shares 
binding sites on DC-SIGN. The globular heads, individually or in 
combination, did not appear to inhibit virus transmission unlike 
full length C1q, suggesting that the collagen domain of C1q and/
or probably oligomeric form of C1q is required for the observed 
inhibitory effect.
In summary, we found that gC1qR can alter C1q–DC-SIGN 
interaction in a way that it promotes viral transfer, thus neutral-
izing the protective effect of C1q. The tripartite complex involv-
ing DC-SIGN–gC1qR-C1q probably leads to an increase in the 
distance between DC-SIGN and C1q that permits DC-SIGN 
interaction with gp120; this allows DC-SIGN and gC1qR to bind 
to the virus with enhanced affinity (Figure 9).
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FigUre 9 | Diagrammatic model explaining the possible implications of the tripartite molecular interplay between Dc-sign, c1q, and gc1qr. (a) 
By virtue of its ability to bind to DC-SIGN on the cell surface, C1q is likely to inhibit interaction between DC-SIGN and HIV-1 gp120, resulting in the inhibition of 
viral transfer. (B) On the DC/Monocyte surface, a trimolecular receptor complex is formed between gC1qR, C1q, and DC-SIGN. Although each of these 
molecules can bind the HIV-1 virus independently, we postulate that it is the binding of the HIV-1 gp-41 to both gC1qR and C1q that initiates the membrane 
fusion before the final binding of gp120 to DC-SIGN and/or CD4, eventually allowing the internalization of the virus. It is possible that HIV-1 interaction with DC/
monocytes causes recruitment of gC1qR to the cell surface, or its secretion, which in turn, can bind to C1q globular heads, thereby neutralizing the protection 
offered by C1q.
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